Home › Compare › INKI vs ABBV

INKI vs ABBV: Dividend Comparison 2026

INKI yields 181.82% · ABBV yields 3.67%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INKI wins by $69.47M in total portfolio value
10 years
INKI
INKI
● Live price
181.82%
Share price
$1.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.51M
Annual income
$33,388,080.18
Full INKI calculator →
ABBV
AbbVie Inc.
● Live price
3.67%
Share price
$168.90
Annual div
$6.20
5Y div CAGR
8.9%
Payout ratio
58%
After 10 yrs · $10,000 · DRIP
Portfolio value
$39.9K
Annual income
$1,154.43
Full ABBV calculator →

Portfolio growth — INKI vs ABBV

📍 INKI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINKIABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INKI + ABBV cover 4 of 12 months — good coverage

Jan
ABBV
Feb
—
Mar
—
Apr
ABBV
May
—
Jun
—
Jul
ABBV
Aug
—
Sep
—
Oct
ABBV
Nov
—
Dec
—
INKI pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INKI
Annual income on $10K today (after 15% tax)
$15,454.55/yr
After 10yr DRIP, annual income (after tax)
$28,379,868.15/yr
ABBV
Annual income on $10K today (after 15% tax)
$312.02/yr
After 10yr DRIP, annual income (after tax)
$981.27/yr
At 15% tax rate, INKI beats the other by $28,378,886.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INKI + ABBV for your $10,000?

INKI: 50%ABBV: 50%
100% ABBV50/50100% INKI
Portfolio after 10yr
$34.78M
Annual income
$16,694,617.31/yr
Blended yield
48.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

INKI
No analyst data
Altman Z
-96.2
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+51.7% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INKI buys
0
ABBV buys
0
No recent congressional trades found for INKI or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINKIABBV
Forward yield181.82% ✓3.67%
Annual dividend / share$2.00$6.20 ✓
Payout ratio50% ✓58%
1-year div growth0%4.7% ✓
5-year div CAGR0%8.9% ✓
Portfolio after 10y$69.51M ✓$39.9K
Annual income after 10y$33,388,080.18 ✓$1,154.43
Total dividends collected$65.15M ✓$7.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: INKI vs ABBV ($10,000, DRIP)

YearINKI PortfolioINKI Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$28,882$18,181.82$11,520$399.75+$17.4K → INKI
2$79,981$49,077.01$13,261$450.98+$66.7K → INKI
3$212,594$127,014.75$15,255$508.41+$197.3K → INKI
4$543,003$315,527.24$17,536$572.74+$525.5K → INKI
5$1,334,202$753,189.45$20,145$644.78+$1.31M → INKI
6$3,157,175$1,729,577.94$23,126$725.38+$3.13M → INKI
7$7,203,193$3,825,015.79$26,532$815.52+$7.18M → INKI
8$15,863,391$8,155,975.05$30,420$916.26+$15.83M → INKI
9$33,760,443$16,786,614.57$34,855$1,028.80+$33.73M → INKI
10$69,511,754$33,388,080.18$39,914$1,154.43+$69.47M → INKI

INKI vs ABBV: Complete Analysis 2026

INKI — Stock

Inky Inc. develops, publishes, and markets mobile software application for smartphones and tablet devices. Its augmented reality app helps users to decide what and where to ink without having to get an actual tattoo. The company was incorporated in 2018 and is based in Larnaca, Cyprus.

Full INKI Calculator →

ABBV — Healthcare

AbbVie is a pharmaceutical giant best known for Humira and newer blockbusters Skyrizi and Rinvoq. A Dividend Aristocrat with 52+ years of consecutive dividend increases. Strong free cash flow generation supports its above-average yield. The company's diversified pipeline reduces dependence on any single drug.

Full ABBV Calculator →
📬

Get this INKI vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INKI vs SCHDINKI vs JEPIINKI vs OINKI vs KOINKI vs MAININKI vs JNJINKI vs MRKINKI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.